Novavax Inc (NVAX) Quote - XNAS | Morningstar

Skip to Content

Is it the right time to buy or sell?

Find out with Morningstar Premium

Is it the right time to buy or sell?

Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax develops product candidates geared toward all age demographics of the general population.

Contact

21 Firstfield Road
Gaithersburg, MD, 20878

T +1 240 268-2000

www.novavax.com

Sector Healthcare

Industry Biotechnology

Most Recent Earnings Sep 30, 2021

Fiscal Year End Dec 31, 2021

Stock Type Speculative Growth

Employees 691

Related

What's in a Meme ETF?

A non-clickbait look into a few clickbait tickers.

Stock Strategist Industry Reports

COVID-19 Vaccine Efficacy Solid Even as Delta Extends Pandemic

Hopes for eradication fade, further highlighting the benefits of vaccination and boosters.

Top Fund Managers Largely Avoided the Market’s Biggest Winners

Outside of vaccine-makers, few owned the fastest risers since the start of 2020.

Stock Strategist Industry Reports

U.S. Herd Immunity Could Be Coming by End of June

Limited vaccine supply in other countries could make global immunity tougher to achieve, though.

Stock Analyst Update

J&J Releases COVID-19 Vaccine Data

The data doesn't significantly alter our valuation or U.S. herd immunity forecast.

Stock Strategist Industry Reports

COVID-19 Sales Have No Major Impact on Drug and Vaccine Manufacturers We Cover

However, the biopharma industry's ability to adapt and innovate to treat disease reinforces our moat ratings.

Stock Strategist Industry Reports

COVID-19 Vaccine Distribution and Herd Immunity to End Pandemic

Successful vaccine development and rollout will boost industry goodwill and reduce ESG risk, but we’re keeping our valuations steady.

Stock Strategist Industry Reports

We Still Expect a Strong U.S. Economic Recovery

Neither the U.S. election outcome nor the coronavirus third wave will derail it.

Preston Caldwell

Investing Specialists

Karen Andersen: The Race for a COVID-19 Vaccine

The Morningstar healthcare strategist discusses the latest on COVID-19, including virus forecasts and vaccine updates from the leading biotech and pharma companies.

Stock Strategist Industry Reports

A Coronavirus Vaccine, or Three, Could Be Available by Year-End

We expect multiple approved vaccines by early 2021 with wide vaccine distribution in developed markets by mid-2021.

Stock Strategist Industry Reports

Timeline Accelerates for COVID-19 Drug Development

Three new vaccines for coronavirus look poised for emergency use authorization in the U.S. this fall.

Transparency is our policy. Learn how it impacts everything we do.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.